An international seminar was held on the challenge of Halal certification in the pharmaceutical industry in Indonesia, analysing the critical issues in this important sector during the Halal certification of pharmaceutical products.
Speakers from the private sector of the pharmaceutical industries and public officials from the regulatory and Halal certification departments of the Indonesian market were present.
The regulation of the pharmaceutical sector in Indonesia from a Halal point of view is still ongoing. The main regulatory reference is the law introduced by the President of the Republic of Indonesia in 2014, which came into force definitively in October 2019. This law makes Halal certification mandatory for all goods (food, cosmetics, pharmaceuticals, chemicals and materials of all kinds) produced domestically or imported from abroad. Products addressed to the Indonesian population not of Islamic faith, which represents only 5% of the population, are exempt from Halal certification. The rest of the population is Muslim.
The most critical subjects present in the medicines, subject to verification during the Halal certification, are: pigments derived from pigs, components derived from microbial cultivation and ethanol.
The Halal market for pharmaceutical products is quite large and is constantly growing. Pharmaceutical consumption in 2018 was USD 92 billion, with an estimated average annual growth rate of 1%.
The largest exporters of pharmaceuticals to the Islamic world, which has around 2 billion consumers, are Germany, France, India, the USA and the UK, in descending order.
The largest Islamic pharmaceutical consumer markets are in descending order: Turkey, Saudi Arabia, Indonesia, Algeria and Pakistan.
For more details on this topic, please contact HD – Halal Development’s experts and consultants (www.halaldevelopment.com), writing to:
Link to the Webinar video: